The industrialist names pharma, obesity clinics and personal fitness among the sectors he expects to gain from wider GLP-1 use.
Recap by typeshit. Post by Harsh Goenka on X.
CNBC's investing team lifts its target on Lilly shares and argues the obesity drug run still has room to grow.
The Pharma Letter looks at how semaglutide generics are changing strategy in India, with Torrent eyeing an expansion into Brazil.
Semafor looks at how little national political figures have said about what the new class of weight loss drugs means for policy.
The doctors take on two of the topics their followers ask about most, giving their verdict on statins and Ozempic.
People on GLP-1 drugs report fewer alcohol cravings, and KTSM says the drugs' popularity is now becoming a challenge for brewers.
Lilly shares jumped 6% to a record high Thursday after earnings beat expectations, with weight loss drug sales leading the way.
Loading…